<DOC>
	<DOCNO>NCT01461941</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety profile E6005 ointment patient atopic dermatitis compare vehicle . The pharmacokinetic profile topical application E6005 also assess .</brief_summary>
	<brief_title>A Phase 2 Study E6005 Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Inclusion Criteria Adults gender age 20 64 year time write informed consent obtain . Outpatients diagnose atopic dermatitis . Exclusion Criteria Patients present illness Kaposi 's varicelliform eruption , scabies , molluscum contagiosum , impetigo contagious , psoriasis , connective tissue disorder , collagen disorder Netherton 's syndrome , etc. , could effect pathological evaluation atopic dermatitis . Patients active infection require oral intravenous administration antibiotic , antifungal antivirus agent/s baseline . Patients advanced disease abnormal laboratory test would possibly affect safety subject implementation study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>Atopic</keyword>
</DOC>